Approximately 29% of Infants Receive RSV Immunization in the 2023-2024 Season
In the 2023-2024 season, nearly 30% of infants in the U.S. received RSV protection via vaccination or monoclonal antibodies, highlighting ongoing efforts to combat severe respiratory infections in newborns.
During the 2023-2024 respiratory virus season, about 29% of infants born between October 2023 and March 2024 in 33 U.S. states and the District of Columbia were immunized against respiratory syncytial virus (RSV). This coverage includes vaccinations administered through infant receipt of nirsevimab and maternal RSV vaccination during pregnancy. Researchers from the CDC, led by Ellen O. Boundy, estimated that 19% of infants received nirsevimab, a monoclonal antibody, while 10% were vaccinated maternally. Notably, 38% of infants given nirsevimab received it within the first week of life. The variation in immunization coverage among states ranged from 11% to 53%. These efforts aim to enhance protection for infants against severe RSV disease, although experts emphasize the need for increased immunization initiatives to better safeguard this vulnerable population.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Wildfire Smoke Exposure Poses Risks for Pregnant Women and Infants in U.S. Communities with Limited Healthcare Access
Wildfire smoke threatens pregnant women and infants in U.S. communities with limited healthcare resources, highlighting urgent public health needs amid climate change. Learn more about the impact and necessary interventions.
Flesh-Eating Bacteria Infections Expanding to New Regions
Infections from Vibrio vulnificus, a dangerous flesh-eating bacteria, are increasingly appearing in new regions due to climate change, posing serious health risks during warmer months.